Refractory Follicular Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2022-04-07
Apr 7, 2022
N
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Suspended
  • Grade 1 Follicular Lymphoma
  • +4 more
  • Bendamustine Hydrochloride
  • +7 more
  • Anchorage, Alaska
  • +422 more
2022-04-05
Apr 5, 2022
N
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
A
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Las Vegas, Nevada
  • +22 more
2022-03-23
Mar 23, 2022
F
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
U
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022
Y
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
N
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Suspended
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +25 more
  • Birmingham, Alabama
  • +23 more
2022-03-05
Mar 5, 2022
C
Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma
Active, not recruiting
  • Grade 3b Follicular Lymphoma
  • +15 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-17
Feb 17, 2022
U
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-18
Feb 18, 2022
C
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
Not yet recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
M
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Active, not recruiting
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-09
Feb 9, 2022
F
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022
M
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma - 2021
Completed
  • Mantle Cell Lymphoma
  • +6 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-18
Jan 18, 2022
B
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +14 more
  • La Jolla, California
  • +1 more
2022-01-10
Jan 10, 2022
J
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Recruiting
  • Recurrent Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Bendamustine Hydrochloride
  • Brentuximab Vedotin
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021
J
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021
N
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Recruiting
  • Recurrent Follicular Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-12-16
Dec 16, 2021
G
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
2021-12-14
Dec 14, 2021
N
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Active, not recruiting
Has Results
  • Grade 3a Follicular Lymphoma
  • +4 more
  • Scottsdale, Arizona
  • +12 more
2021-12-15
Dec 15, 2021
M
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-22
Nov 22, 2021
V
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Birmingham, Alabama
  • +4 more
2021-11-09
Nov 9, 2021
O
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +11 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-09-29
Sep 29, 2021
N
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma - 2021
Completed
Has Results
  • Recurrent Follicular Lymphoma
  • +10 more
  • Denver, Colorado
  • +10 more
2021-09-04
Sep 4, 2021
M
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
2021-08-10
Aug 10, 2021